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ABSTRACT 
Methionine adenosyltransferase α1 (MATα1, encoded by MAT1A) is responsible for hepatic 
biosynthesis of S-adenosylmethionine, the principal methyl donor. MATα1 also act as a 
transcriptional co-factor by interacting and influencing the activity of several transcription 
factors. Mat1a knockout (KO) mice have increased levels of cytochrome P450 2E1 
(CYP2E1), but the underlying mechanisms are unknown. The aims of the current study were 
to identify binding partners of MATα1 and elucidate how MATα1 regulates CYP2E1 
expression. We identified binding partners of MATα1 by co-immunoprecipitation (co-IP) and 
mass spectrometry. Interacting proteins were confirmed using co-IP using recombinant 
proteins, liver lysates and mitochondria. Alcoholic liver disease (ALD) samples were used to 
confirm relevance of our findings. We found MATα1 negatively regulates CYP2E1 at mRNA 
and protein levels, with the latter being the dominant mechanism. MATα1 interacts with 
many proteins, but with a predominance of mitochondrial proteins including CYP2E1. We 
found MATα1 is present in the mitochondrial matrix of hepatocytes using immunogold 
electron microscopy. Mat1a KO hepatocytes had reduced mitochondrial membrane potential 
and higher mitochondrial reactive oxygen species, both of which were normalized when 
MAT1A was overexpressed. In addition, KO hepatocytes were sensitized to ethanol and tumor 
necrosis factor α-induced mitochondrial dysfunction. Interaction of MATα1 with CYP2E1 
was direct and this facilitated CYP2E1 methylation at R379 leading to its degradation via the 
proteasomal pathway. Mat1a KO livers have a reduced methylated/total CYP2E1 ratio. 
MATα1’s influence on mitochondrial function is largely mediated by its effect on CYP2E1 
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expression. Patients with ALD have reduced MATα1 levels and a decrease in 
methylated/total CYP2E1 ratio. Conclusion: Our findings highlight a critical role of MATα1 
in regulating mitochondrial function by suppressing CYP2E1 expression at multiple levels. 
 
S-adenosylmethionine (SAMe) is the principal biological methyl donor of the cell that is
synthesized by methionine adenosyltransferase (MAT), an enzyme encoded by the MAT 
gene, which is one of the 482 essential genes required for survival (1). Two genes in 
mammals (MAT1A and MAT2A) encode for the catalytic subunits MATα1 and MATα2. The 
former is expressed largely in normal liver and the latter is expressed in all extrahepatic 
tissues (1). Patients with chronic liver disease have reduced hepatic MAT activity, due to 
both a decrease in MAT1A mRNA levels and inactivation of MATα1 protein itself (1). 
MAT1A expression is reduced in individuals with alcoholic hepatitis (2), non-alcoholic fatty 
liver disease (NAFLD) with more advanced fibrosis (3), in nearly 90% of cirrhotic patients 
(4) and in most hepatocellular carcinoma (HCC) (4-5). Mat1a knockout (KO) mice have
chronic hepatic SAMe deficiency, spontaneously develop steatohepatitis and HCC (6-7). 
These mice are also sensitized to carbon tetrachloride (CCl4)-induced hepatotoxicity, due to 
higher cytochrome P450 2E1 (CYP2E1) expression (7) and display a decrease in 
mitochondrial membrane potential (8). However, the underlying mechanism for increased 
CYP2E1 expression is unknown and whether this contributes to a lower mitochondrial 
membrane potential in Mat1a KO mice is also unclear.  
 
CYP2E1 has been implicated in numerous diseases and its expression is upregulated in 
alcoholic liver disease (ALD) (9-10) and NAFLD (11-12). CYP2E1 has been shown to be 
localized within several subcellular compartments including the ER, Golgi apparatus and 
within the mitochondrial matrix (13-17). It has been suggested that CYP2E1-mediated 
damage to mitochondrial membrane potential and function, through the production of 
reactive oxygen species (ROS), may be an early event in liver injury (9-10).  
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We recently showed that MATα1 interacts with proteins such as c-MYC and MAX to 
modulate E-box dependent gene expression (18, 19). The aims of this work were to further 
define what proteins could interact with MATα1 and to explore how MATα1 regulates 
CYP2E1 expression and mitochondrial function. Here, we revealed the novel finding that 
MATα1 is localized to the mitochondrial matrix where it interacts with CYP2E1 to influence 
mitochondrial membrane potential and generation of ROS. Our results revealed a novel role 
of MATα1 in providing a mitochondrial source of SAMe in hepatocytes; and that it 
negatively regulates CYP2E1 protein stability via methylation at a critical arginine residue.  
 
EXPERIMENTAL PROCEDURES 
 
Mat1a KO and wild type (WT) mice experiments 
Mat1a KO mice were previously described (6). Four-month old male KO and WT littermates 
were used for this study unless specified in the figure legend. Some mice were used for 
isolation of hepatocytes as described (20), whilst other mice livers were used for RNA, 
protein analysis and isolation of mitochondria as described in additional methods.  
 
Female WT mice were treated with ethanol or pair-fed control diet following the protocol of 
the NIAAA model (21). Please see additional methods for details. 
 
Human samples 
Liver specimens from subjects with ALD (N=5) were obtained from the explant during liver 
transplantation. All had history of alcohol consumption averaging at least 80 g/d for men or 
50 g/d for women, for at least 10 years (22). This criterion is based on epidemiological 
evidence of the alcohol consumption and cirrhosis relationship (23). We excluded patients 
with hepatitis B or C, autoimmune liver disease, hemochromatosis, Wilson's disease, and 
HCC. Patients’ clinical characteristics are shown in Supplementary Table 1. Liver samples 
from controls (N=4) were from subjects with no known history of excessive alcohol use or 
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underlying chronic liver disease. They were obtained during abdominal surgeries for various 
causes.  
 
Mitochondrial membrane potential and ROS measurements 
Mitochondrial membrane potential was measured using the MitoProbe™ JC-1 (Molecular 
Probes, Eugene, OR) assay kit following the protocol provided. Mitochondrial ROS was 
measured using the MitoSOX™ Red kit (Molecular Probes, Eugene, OR) according to the 
manufacture’s guide. Five μM antimycin A was added 10 minutes after (SML0737, Sigma, St 
Louis, MO) or 5 μM of MitoTEMPO was added an hour prior to the start of the assay for 
positive and negative controls, respectively. 
 
Additional methods 
All other methods used are described in detail in the ‘Supplemental Methods’ section of the 
online supporting information. 
 
 
RESULTS 
 
MATα1 interactome includes a predominance of mitochondrial proteins 
To define the MATα1 interactome, we performed immunoprecipitation (IP) with an anti-
MATα1 antibody (Ab) using liver lysates from WT and Mat1a KO mice. Proteins were then 
separated on SDS-PAGE and identified using mass spectrometry (MS). Silver stain was used 
to highlight the differences between the WT and Mat1a KO mice samples (Supplemental Fig. 
1A). Of the top 24 highest scoring proteins, 11 of them were mitochondrial (Supplemental 
Table 2). To further examine the MATα1 interactome, GO and KEGG pathways enrichment 
analysis were performed using the STRING database (https://string-db.org/). Of the total 375 
proteins, 40% were classified as mitochondrial with most of them associated to the 
mitochondrial matrix and inner mitochondrial membrane (Supplemental Fig. 1B-C). 
Additionally, the main mitochondrial metabolic pathways including glycolysis, the 
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tricarboxylic cycle, and oxidative phosphorylation were all enriched (Supplemental Fig. 1D). 
CYP2E1, a protein that is elevated in the Mat1a KO mouse liver that can also target the 
mitochondria, was also identified (Supplemental Table 2). 
 
MATα1 is localized to the mitochondrial matrix of hepatocytes 
Since mitochondrial proteins account for such a high proportion of the MATα1 interactome, 
we next examined whether MATα1 was localized within the mitochondria. Isolation of 
mitochondria from WT mice liver revealed the presence of MATα1 within this organelle 
(Fig. 1A). To determine localization within the mitochondria, WT mice liver mitochondria 
were subjected to subfractionation with chemical agents to access the different compartments, 
followed by Western blotting with known marker proteins of each mitochondrial 
compartment, which revealed MATα1 to be in the matrix as shown in the final column (Fig. 
1B). To confirm the matrix location of MATα1 and rule out the possibility of contamination 
from the other cellular compartments, immunogold electron microscopy (EM) was performed 
using WT mouse liver and the presence of MATα1 can be seen as discrete concentric gold 
particles within the mitochondrial matrix and cytosol (Fig. 1C left panel) which are absent in 
the negative control (Fig. 1C right panel, Supplemental Fig. 2).  
 
MATα1 interacts with molecular chaperones and its mitochondrial targeting requires 
HSP70A8  
MATα1’s presence in the mitochondrial matrix of hepatocytes prompted us to question how 
this protein is targeted to this organelle. Since MATα1 contains no mitochondrial targeting 
sequence to aid localization to the mitochondria as determined by multiple organelle 
localization prediction servers (TargetP, Multiloc and MitoFates), other known mechanisms 
of protein trafficking to the mitochondria were studied, namely the use of heat shock proteins 
(HSP) (24). HSP70A8 and HSP90β, HSPs known to be involved in protein trafficking, were 
identified to interact with MATα1 (Supplemental Table 2). IPs using WT mouse liver were 
carried out and showed that MATα1 interacts with the cytosolic molecular chaperones 
HSP70A8 and HSP90β (Fig 2A-B). When HSPA8 was knocked down in HepG2 cells, 
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MATα1 levels decreased in the mitochondrial fraction by 45% suggesting that HSP70A8 
plays an important role in MATα1 localization to the mitochondria (Fig 2C-D, and second 
siRNA shown in Supplemental Fig. 3A). In contrast, when HSP90AB1 was knocked down, 
mitochondrial MATα1 also fell by 32% but this was due to a drop by the same amount of 
cytosolic MATα1 (Fig. 2E-F, and second siRNA shown in Supplemental Fig. 3B). 
 
MATα1 affects mitochondrial function, mitochondrial ROS and mitochondrial membrane 
potential 
It was previously reported that Mat1a KO mice had reduced mitochondrial membrane 
potential (8), so functional experiments were explored to evaluate the effect of MATα1 on 
mitochondrial function. Consistent with previously published data (8), we found the 
hepatocytes from the Mat1a KO mouse showed a 40% reduction in mitochondrial membrane 
potential as compared to WT hepatocytes, which could be restored upon the overexpression 
of MAT1A (Fig. 3A). Levels of mitochondrial ROS (mROS) were elevated in Mat1a KO 
hepatocytes by 30% and were normalized to WT level after MAT1A overexpression (Fig. 
3A). To rule out the possibility of spurious signals in the mROS experiments, we included 
either antimycin A, an inhibitor to the mitochondrial respiration complex III, or the 
superoxide scavenger mitoTEMPO as positive and negative controls, respectively 
(Supplemental Fig. 3C-E). Using WT hepatocytes, overexpressing MAT1A increased the 
mitochondrial membrane potential (25%) whilst silencing caused the opposite effect (Fig. 3B, 
and second siRNA shown in Supplemental Fig. 4A). mROS levels fell in WT hepatocytes 
upon the overexpression of MAT1A (25%), and levels increased by 30% when MAT1A was 
silenced (Fig. 3B, and second siRNA shown in Supplemental Fig. 4A). Silencing MAT1A in 
HepG2 cells had the same effect as in WT hepatocytes, lower membrane potential (20%) and 
higher mROS levels (35%) as compared to the scramble control (Fig. 3C, and second siRNA 
shown in Supplemental Fig. 4B).   
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To examine whether Mat1a KO hepatocytes are sensitized to stress, mitochondrial membrane 
potential and mROS were measured after treatment with either tumor necrosis factor α 
(TNFα) or ethanol. TNFα had no significant effect on WT hepatocytes but it caused a 17% 
decrease in membrane potential and a 40% increase in mROS levels in Mat1a KO 
hepatocytes (Supplemental Fig. 4C). Interestingly, ethanol addition resulted in a 50% 
increase in membrane potential of WT hepatocytes, but lowered the membrane potential of 
Mat1a KO hepatocytes by 22% (Supplemental Fig. 4D). Ethanol induced mROS in WT 
hepatocytes by 50% but caused nearly a 2-fold increase in Mat1a KO hepatocytes 
(Supplemental Fig. 4D).  
To further study the effects of MATα1 on mitochondrial function we performed respirometry 
experiments. The oxygen consumption rate (OCR) was 30% lower in isolated liver 
mitochondria from Mat1a KO mice as compared to WT (Fig. 3D). Silencing of MAT1A in 
HepG2 cells significantly decreased basal respiration, ATP production, the maximum 
respiratory capacity, and the reserve capacity (Fig 3E, and second siRNA shown in 
Supplemental Fig. 4E). 
 
MATα1 and CYP2E1 interact with each other directly 
CYP2E1, a protein known to target to mitochondria and one that generates ROS, was 
identified by MS as a potential binding partner of MATα1 (Supplemental Table 2). To 
confirm this interaction, we performed pulldown assays with purified recombinant proteins 
and a series of IP experiments. Direct interaction between CYP2E1 and MATα1 was 
demonstrated using recombinant proteins (Fig. 4A-B), whilst endogenous interaction was 
demonstrated by co-IP in both mouse liver lysates (Fig. 4C) and in isolated mouse liver 
mitochondria (Fig. 4D).  
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MATα1 negatively regulates CYP2E1 expression 
We next examined how MATα1 influences CYP2E1 expression and the functional outcome 
of their interaction. Levels of Cyp2e1 mRNA were increased by 50% in Mat1a KO mice 
livers compared to the WT control (Fig 5A), whilst CYP2E1 protein levels in the Mat1a KO 
livers were 4.6-fold of the WT controls, suggesting the predominant mechanism for increased 
CYP2E1 expression lies at the protein level (Fig. 5B). Isolated mitochondria from WT and 
Mat1a KO mice livers showed a 54% increase in mitochondrial CYP2E1 level in the Mat1a 
KO (Fig. 5C). This increase was also confirmed using MS (Fig 5D). Since the dominant 
mechanism of MATα1-mediated suppression of CYP2E1 lies at the protein level we 
investigated how this occurs and the functional consequences. 
 
MAT1A knockdown-mediated mitochondrial dysfunction is CYP2E1 dependent 
CYP2E1 is known to influence mitochondrial function (10), which prompted us to examine 
whether MAT1A-mediated changes in CYP2E1 expression could play an important role in 
mitochondrial function. Knockdown of MAT1A in WT mouse hepatocyte cells doubled 
CYP2E1 protein abundance; whilst knockdown of CYP2E1 did not change the level of 
MATα1 expression, it prevented MAT1A knockdown-mediated CYP2E1 induction (Fig. 5E, 
and second siRNA shown in Supplemental Fig. 5A). Knockdown of MAT1A decreased 
mitochondrial membrane potential by 25% whilst mROS levels increased by 25%. 
Knockdown of CYP2E1 resulted in a 30% increase in mitochondrial membrane potential and 
a 30% decrease in mROS. Combined knockdown of MAT1A and CYP2E1 caused no change 
in membrane potential but the increase in mROS after MAT1A knockdown was blocked (Fig. 
5F, and second siRNA shown in Supplemental Fig. 5B).   
 
CYP2E1 is methylated and methylated-CYP2E1 (me-CYP2E1) level is reduced in Mat1a 
KO liver mitochondria 
Interaction of MATα1 and CYP2E1 raised the possibility that CYP2E1 might be methylated 
and this could regulate its protein stability. Co-IP using both WT and Mat1a KO mice liver 
mitochondria with anti-mono/di-methyl arginine Ab followed by immunoblotting (IB) for 
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CYP2E1 revealed CYP2E1 to be methylated and methylated CYP2E1 (me-CYP2E1) levels 
were higher in the WT mitochondria compared to the Mat1a KO, while total CYP2E1 protein 
levels were higher in the Mat1a KO, resulting in an 70% decrease in me-CYP2E1/total 
CYP2E1 ratio (Fig. 6A). The decrease in methylated CYP2E1 in Mat1a KO mouse liver 
mitochondria was also confirmed using MS (Fig. 6B-C).  
  
MATα1-mediated down-regulation of CYP2E1 protein level requires R379 methylation  
To identify the possible site of methylation on CYP2E1, methylation prediction servers were 
run using the human CYP2E1 protein sequence which led to the identification of two arginine 
residues, R100 and R379 (Supplemental Table 3). Mutation of these residues to asparagine, 
both single and double mutations, and overexpression in HepG2 cells showed that they were 
stably expressed to a level comparable to WT CYP2E1 (Fig 6D). Interestingly, when MAT1A 
was also overexpressed a clear reduction in WT and R100N CYP2E1 was observed (50%), 
but this reduction did not occur when R379N or the double mutant CYP2E1 was 
overexpressed, suggesting that R379 is critical for MATα1-dependent CYP2E1 degradation 
(Fig. 6D).  
 
MATα1 reduces the half-life of CYP2E1 and aids its degradation through the proteasomal 
pathway 
To examine the effect that methylation had on the stability of CYP2E1, CYP2E1 was 
overexpressed alone or with MAT1A prior to using cycloheximide (CHX) to stop de novo 
protein synthesis in HepG2 cells. Overexpression of MAT1A significantly reduced the t1/2 of 
co-expressed CYP2E1 by almost 40% (Fig. 7A-B). To see whether the effect of MAT1A 
overexpression is mediated by enhanced proteasomal degradation of CYP2E1, HepG2 cells 
were transfected with CYP2E1-DDK, with or without MAT1A overexpression vectors and 
treated with the proteasomal inhibitor MG132. Figure 7C shows that MG132 completely 
abolished MAT1A overexpression-mediated down-regulation of CYP2E1 protein level. We 
further examined the effects of MG132 by performing a time course over six hours. CYP2E1 
protein levels remained relatively stable over six hours, but upon addition of MG132 
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CYP2E1 levels nearly doubled over the same time course (Supplemental Fig. 6A). When 
MAT1A is co-overexpressed there is a slight decrease in the levels of CYP2E1, which was 
blocked upon MG132 treatment (Supplemental Fig. 6B).   
 
As MAT1A overexpression-mediated down-regulation of CYP2E1 protein level seemed to 
occur through the proteasomal degradation pathway we examined whether MATα1 was also 
localized in the microsome. Upon isolation of microsomes from mouse liver, the presence 
MATα1 could be seen via Western blot, along with calnexin, a marker of the endoplasmic 
reticulum, and absence of tubulin, a marker of the cytosol, to show the purity of the isolation 
(Fig 7D). Further IP studies revealed that MATα1 and CYP2E1 also interact in this 
subcellular compartment (Fig 7E-F). 
 
It has been reported that levels of CYP2E1 fall during hepatocyte dedifferentiation (25), so 
we compared CYP2E1 protein expression in WT and Mat1a KO hepatocytes cultured for 48 
hours. Consistent with previous reports (25), levels of CYP2E1 fell in WT hepatocytes by 
50% over 48 hours. CYP2E1 levels also fell in Mat1a KO hepatocytes but by 48 hours its 
level was much higher than that of WT hepatocytes (Supplemental Fig. 6C). 
 
Levels of CYP2E1 and me-CYP2E1 are increased in human ALD and a mouse model of 
chronic and binge ethanol feeding  
To extend our observations to pathophysiological state in humans, we determined the 
mitochondrial presence of MATα1 and its interaction with CYP2E1, levels of MATα1 
protein as well as methylated CYP2E1 levels in the liver tissues of subjects with ALD, a 
known liver condition with increased protein expression of CYP2E1. Normal human liver 
showed the presence of MATα1 within the mitochondria (Fig. 8A). The endogenous 
interaction of MATα1 and CYP2E1 was confirmed by performing co-IP (Fig. 8B). Consistent 
with lower MAT1A mRNA levels in ALD (2), MATα1 protein levels are reduced in ALD as 
compared to normal controls (Fig. 8C). CYP2E1 is methylated in human liver samples and 
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those from ALD patients have higher total CYP2E1 level but a lower me-CYP2E1 to total 
CYP2E1 ratio as compared to normal controls (Fig. 8D), which was similar to what’s 
observed in the Mat1a KO animal model (Fig 6A). Furthermore, similar to human ALD, 
samples from the NIAAA mouse model, a model of chronic and binge ethanol feeding (21), 
showed that the me-CYP2E1 to total CYP2E1 ratio was lower as compared to pair-fed 
controls (Fig. 8E).     
 
DISCUSSION 
 
Up until recently the general understanding has been that MAT1A-encoded isoenzymes are 
cytosolic and provide SAMe biosynthesis in normal liver. It is well accepted that MAT1A 
expression and SAMe levels fall in chronic liver disease and HCC (1). Mice lacking Mat1a 
have higher total lipid peroxides in serum, altered mitochondrial membrane potential, are 
sensitized to CCl4-induced hepatotoxicity due to higher CYP2E1 expression, and 
spontaneously develop steatohepatitis and HCC (6-7). Much of the phenotype of Mat1a KO 
mice was thought to be consequences of cytosolic SAMe deficiency, although how SAMe 
deficiency resulted in increased CYP2E1 expression was unclear. More recently others and 
we have shown MATα1 can target the nuclear compartment where it can regulate gene 
expression by epigenetic mechanisms (26-28). In addition, we recently showed MATα1 
interacts directly with MAX and c-MYC and negatively regulate E-box-driven reporter 
activity (19). This prompted us to investigate the MATα1 interactome, which revealed the 
unexpected high number of mitochondrial proteins, including CYP2E1 (Supplemental Table 
2). In the course of these investigations we unveiled two main novel findings. First is that 
MATα1 is targeted to the mitochondria where it plays an important role in regulating 
mitochondrial function, and second is that MATα1’s importance in mitochondrial function is 
related to its ability to negatively regulate CYP2E1 expression.  
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
It has been known for a long time that Mat1a KO mice have lower mitochondrial membrane 
potential, which was thought to be due to reduced prohibitin 1 (PHB1) expression (8). PHB1 
is an important mitochondrial chaperone protein whose stability is regulated by the SAMe 
level (8). However, when we noticed that 40% of all the interacting proteins and 46% of the 
top MATα1 interacting proteins were mitochondrial, we examined more closely whether 
MATα1 could also target the mitochondria (Supplemental Fig. 1, Supplemental Table 2). 
Using a variety of tools from co-IP, mitochondrial subfractionation to finally immunogold 
EM, we demonstrated the unequivocal presence of MATα1 in the mitochondrial matrix (Fig. 
1, Supplemental Fig. 2). Previous investigations highlighted the importance of SAMe within 
the mitochondria, which led to the identification of the SAMe channel transporter, 
SLC25A26, that was believed to be the only mechanism to allow SAMe entry into the 
mitochondrial matrix in cells (29). Members of the SLC25 family encode for mitochondrial 
carriers that are membrane embedded proteins, which translocate solutes across the inner 
mitochondrial membrane (29-30). The importance of SAMe within the mitochondria can be 
seen in patients that have mutations resulting in non-functional SLC25A26 proteins. Three 
cases of SLC25A26 mutations have been reported where a lack of a functional channel 
caused lactic acidosis, cystic necrosis of the germinal matrix, and cardiopulmonary failure 
(31). Interestingly, there was no mention of any liver abnormality. Although hepatocytes also 
express this channel (data not shown), presence of MATα1 in the mitochondrial matrix 
suggest it can also provide a local source of SAMe, which may be necessary as SAMe has a 
half-life of only about 5 min (32) and is competed for by hundreds of enzymes (33). The fact 
that liver is where 85% of all transmethylation reactions take place (1) supports the notion 
that having MATα1 near important substrates in the mitochondria facilitates their regulation 
by methylation.  
 
Targeting of MATα1 to the mitochondrial matrix essentially involves two stages: i) targeting 
to, and recognition by the mitochondria and ii) translocation through the outer and inner 
membrane by import machinery. MATα1 does not contain the classical amino-terminal 
cleavable presequence for mitochondrial targeting as determined by TargetP, Multiloc and 
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MitoFates, or an internal mitochondrial intermembrane space signal that would directly target 
it to the mitochondria (34). One well-established method of mitochondrial protein recruitment 
is through HSPs, which play a major role in trafficking proteins to and across the 
mitochondria membranes (24). From MS results, multiple HSPs were found to potentially 
interact with MATα1, including the constitutively expressed cytosolic chaperones, HSP70A8 
and HSP90β, as well as several mitochondrial matrix HSPs, including HSP60, HSP70A9 and 
TRAP-1 (Supplemental Table 2). Co-IP experiments using mouse liver lysate showed that 
MATα1 interacted with the cytosolic HSP proteins HSP70A8 and HSP90β, suggesting that 
they may facilitate successful transport of MATα1 to the mitochondria (Fig. 2A-B). Our 
finding that knockdown of HSPA8 reduced the amount of MATα1 in the mitochondria by 
45% (Fig. 2C-D, Supplemental Fig. 3A) is consistent with the notion that HSP70A8 plays an 
important role in MATα1 mitochondrial targeting. Interestingly silencing of HSP90AB1 
reduced the cytosolic and mitochondrial MATα1 fraction by around 40% suggesting that this 
chaperone may play a role in the maturation of MATα1 rather than aiding its translocation to 
the mitochondria (Fig. 2E-F, Supplemental Fig. 3B). Further studies are needed to elucidate 
the precise mechanism of entry into the mitochondrial matrix.  
 
Even though Mat1a KO mice livers are known to have lower mitochondrial membrane 
potential (8), mitochondrial function had never been directly assessed. Utilizing the 
mitochondrial Seahorse analyzer with both a cellular system and isolated mitochondria, we 
examined whether MATα1 modulates mitochondrial respiration and energy production in the 
liver. For that, we isolated liver mitochondria from WT and Mat1a KO mice and measured 
real-time oxygen consumption as a readout of oxidative phosphorylation. In addition, to be 
able to determine key parameters of mitochondrial function we silenced MAT1A in HepG2 
cells. As expected, our studies show that MATα1 positively regulates mitochondrial function 
in the liver both in vitro and in vivo. Its absence significantly decreased ADP-stimulated 
respiration in isolated liver mitochondria (Fig. 3D) and basal respiration and ATP-linked 
respiration in HepG2 cells (Fig. 3E, Supplemental Fig. 4E). The maximal respiratory 
capacity, which shows the maximum rate of respiration that the cell can achieve and mimics 
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the physiological energy demand, and also the reserve capacity, which is an estimate of the 
potential bioenergetic reserve the cell can call upon in times of stress, were significantly 
reduced upon MAT1A silencing. We also found that Mat1a KO hepatocytes were much more 
susceptible to the effects of TNFα and ethanol on mitochondrial function. TNFα had little 
effect on WT hepatocytes but raised mROS and lowered mitochondrial membrane potential 
in Mat1a KO hepatocytes (Supplemental Fig 4C). Similarly, ethanol raised mROS levels 
much more in KO hepatocytes. Intriguingly, ethanol treatment increased membrane potential 
in WT hepatocytes but lowered it in KO hepatocytes (Supplemental Fig. 4C). Our results are 
consistent with a previous report that showed ethanol hyperpolarized mitochondrial 
membrane potential in mouse myocardial cells (35). Taken together, these results support a 
major role of MATα1 in mitochondrial function.  
 
Amongst the MATα1 interacting proteins we focused on CYP2E1 because our earlier study 
showed Mat1a KO mice are sensitized to CCl4-induced liver injury and this was due to 
increased CYP2E1 expression and activity (7). CYP2E1 is an important target as its induction 
is implicated in a variety of human diseases, including diabetes, ALD and NAFLD (36). A 
marked increase in mitochondrial CYP2E1 content is associated with mitochondrial oxidative 
stress, suggesting a direct role of CYP2E1 in ROS production (17, 37). Our study found that 
MATα1 regulates CYP2E1 expression negatively by two different mechanisms. One is at the 
mRNA level as Cyp2e1 mRNA level increased by 50% in Mat1a KO mice (Fig. 5A) and the 
second is at the protein level, as Mat1a KO mice had a 4.6-fold increase in CYP2E1 in total 
protein level (Fig. 5B). CYP2E1 induction in many instances (such as by alcohol) also occurs 
largely at the post-translational level by regulating its proteasomal degradation (10). This 
prompted us to devote our efforts to elucidate how MATα1 regulates CYP2E1 at the protein 
level and examine the functional consequences.  
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We found that recombinant MATα1 and CYP2E1 can directly interact in vitro, and 
endogenous proteins interact in total, mitochondrial, and microsomal lysates (Fig. 4, Fig. 7E-
F). Since we speculated that mitochondrial MATα1 may be providing a local source of SAMe 
to methylate its targets, we next examined whether CYP2E1 might be methylated. Indeed, we 
found lower methylated CYP2E1 but higher total CYP2E1 in the KO mitochondria (Fig. 6A), 
suggesting methylation of CYP2E1 may destabilize the protein. This was also true in human 
ALD, a disease where MATα1 is decreased, CYP2E1 is increased and total liver lysate 
showed a reduction in me-CYP2E1 (Fig. 8C-D). A similar decrease in me-CYP2E1 to total 
CYP2E1 ratio also occurred in the NIAAA mouse model (Fig. 8E). Methylation prediction 
servers highlighted several arginine residues as possible candidates but did not predict any 
lysine residues (Supplemental Table 3). Analysis of the human CYP2E1 crystal structure 
(PDB:3T3Z) showed that R379 would be the most likely target of methylation as its side 
chain was surface accessible unlike R100 whose side chain was involved in forming 
hydrogen bonds with the protoporphyrin IX moiety of CYP2E1 (Supplemental Fig. 7A-C). 
Mutagenesis studies confirmed that R379 of CYP2E1 is the critical residue that is required 
for MATα1 overexpression to destabilize CYP2E1 (Fig 6D). To the best of our knowledge 
CYP2E1 has not been shown to be methylated. Although our current study is mainly focused 
on the mitochondria, it is highly likely that methylation of CYP2E1 is also occurring in the 
other cellular compartments such as the ER and may similarly affect its stability, as we also 
found MATα1 to be present in the microsomal fraction where it interacts with CYP2E1 (Fig 
7D-F).  
 
We also examined the effect MATα1 had on the degradation of CYP2E1. Overexpression of 
MATα1 reduced the amount of CYP2E1 protein, but this effect was blocked upon the 
addition of MG132, a proteasomal inhibitor (Fig. 7C), supporting our notion that methylation 
of CYP2E1 at R379 enhances CYP2E1 degradation through the proteasomal system. To this, 
upon blocking of de novo protein synthesis by CHX, addition of MAT1A reduced the t1/2 of 
CYP2E1 from 5 to 3 hours (Fig. 7A-B), further providing evidence that methylation of 
CYP2E1 leads to its decreased protein stability. The rapid phase degradation of CYP2E1 has 
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been reported to have a t1/2
 
between 3-6 hours in rat hepatoma cells (38-39) and between 2.5-
6 hours in HepG2 cells expressing human CYP2E1 (40), which is consistent with our 
findings. Although there are proteases within the mitochondria there is no proteasomal 
system, so how mitochondrial methylated CYP2E1 could be degraded is not clear. One 
possible explanation is that upon methylation, CYP2E1 is transported out of the mitochondria 
for degradation via the proteasomal degradation system. There is evidence of proteins being 
transported out of the mitochondria as a recent report by Sutendra et al (41) described the 
accumulation of pyruvate dehydrogenase in the nucleus in the S-phase of the cell cycle where 
it participated in histone acetylation. It was devoid of presequences, suggesting that the 
proteins interacted with mitochondrial processing peptidase prior to nuclear 
translocation.  Lavie et al (42) recently published that the inner mitochondrial matrix protein 
SDHA was found ubiquitinated within the mitochondrial but did not identify if this 
modification occurred before protein entry into the mitochondria. Although the mitochondrial 
matrix is not accessible to the cytosolic proteasome, the outer mitochondrial membrane is. 
Ubiquitination of key mitochondrial outer membrane proteins can alter mitochondrial 
dynamics through fusion (mitofusins) and fission (DRP1 and FIS1) of mitochondria (43). The 
ubiquitination proteasome-mediated degradation of the mitofusin proteins MFN1 and MFN2 
in damaged mitochondria is necessary in order to prevent fusion with healthy mitochondria 
and favor fragmentation instead (43). Whether loss of MAT1A leads to a difference in the 
mitochondrial ubiquitination pattern is an intriguing topic for future investigation.  
 
Since an increase in mitochondrial CYP2E1 can cause mitochondrial dysfunction (10), we 
examined what role increased CYP2E1 expression played in the MAT1A knockdown-
mediated mitochondrial dysfunction. We found MAT1A knockdown mediated fall in 
mitochondrial membrane potential and increase in mROS required CYP2E1 induction (Fig. 
5E-F), which support an important role for CYP2E1. However, we cannot exclude 
participation of other mitochondrial proteins that interact with MATα1, such as ATP synthase 
(Supplemental Table 2). Future studies will examine whether these proteins are methylated 
and whether methylation alters their functionality.  
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In summary, our current study showed MATα1 is targeted to the mitochondrial matrix in 
hepatocytes to provide an immediate source of SAMe to important substrates that are 
regulated by methylation. MATα1 negatively regulates CYP2E1 expression mainly at the 
protein levels. Our data support CYP2E1 methylation at R379 enhances its proteasomal 
degradation. These findings may help explain the consequences of MAT1A down-regulation 
that occur in many chronic human diseases including ALD where there is a decrease in 
MATα1, me-CYP2E1 and an increase in total CYP2E1 levels.  
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FIGURE LEGENDS 
Figure 1. MATα1 is localized to the mitochondrial matrix in liver 
A. Western blot analysis of MATα1 in whole mouse liver showing both cytosolic and
mitochondrial fractions. Mitochondrial (COX IV) and cytosolic (Tubulin) specific markers 
were immunoblotted to demonstrate fraction purity (n=3). B. Subfractionation of mouse liver 
(n=3) treated with Proteinase K (PK), Digitonin (Dig) and/or TritonX-100 (TTX). For the 
different mitochondrial compartments VDAC (outer membrane), COX IV (inner membrane), 
Cytochrome C (intermembrane space and inner membrane), SDHA (matrix). C. 
Immunogold-EM of WT mouse liver (n=2) mitochondria showing presence of MATα1 in the 
mitochondrial matrix (left panel, distinct concentric circles) as compared to the absence of a 
specific signal in the no Ab negative control (right panel). Black arrows indicate MATα1. 
Images are 80,000X magnification.  
Figure 2. MATα1 interacts with heatshock proteins and requires HSP70A8 to gain 
entry into the mitochondria 
A. IP of WT mouse liver lysate (700 μg, n=3) with anti-MATα1 or anti-HSP70A8 Ab
followed by Western blot analysis with HSP70A8 or MATα1. B. IP of WT mouse liver lysate 
(700 μg, n=3) with anti-MATα1 or anti-HSP90β Ab followed by Western blot analysis with 
HSP90β or MATα1. Blots were re-probed with Ab used for IP. Normal Ig was used as a 
negative control, 10 µg of lysate used in the IP were loaded as input control. C. Western blot 
analysis of cytosolic and mitochondria fraction of HepG2 cells (n=3) after silencing of 
HSPA8 (100 nM) for 72 hours. Tubulin was used a cytosolic marker, while COX IV was used 
as a mitochondrial marker. Actin was used as housekeeping control to normalize protein 
expression. D. Graph summarizes the densitometric values expressed as % of scramble 
control (SC) from three independent experiments, *P < 0.05 versus SC. E. As in C but after 
silencing of HSP90AB1 (30 nM).  F. As in D. 
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Figure 3. Mat1a KO mice mitochondria have elevated mROS production and reduced 
membrane potential 
A. Membrane potential and mitochondrial ROS (mROS) of isolated wild type (WT), Mat1a
knockout (KO) hepatocytes and Mat1a KO hepatocytes overexpressing MAT1A (48 hours, 
N=3). *P < 0.05 versus WT, tP < 0.05 versus KO. B. Membrane potential and mROS 
production were measured in WT mouse hepatocytes where MAT1A was either over-
expressed (48 hours) or knocked down (66 hours, 50 nM) (n=3). *P < 0.05 versus empty 
vector (EV), tP < 0.05 versus scramble control (SC). C.  Membrane potential and mROS 
levels in HepG2 cells with MAT1A knock down (66 hours, 25 nM) (n=3). *P < 0.05 versus 
SC. D.  Mitochondrial respiration in isolated liver mitochondria from 7 month old female WT 
and Mat1a KO mice. Values are represented as mean ± SEM (n=6 replicates from three 
independent experiments). *P < 0.05 Mat1a KO versus WT. E. Oxygen consumption rate 
(OCR) measured in HepG2 cells with MAT1A  knockdown. Oligomycin (Oligo) inhibits ATP 
synthesis, FCCP uncouples oxidative phosphorylation, rotenone (Rot) inhibits mitochondrial 
complex I and antimycin A (AA) inhibits complex III in the respiratory chain. OCR profile 
was normalized to protein level. Basal and ATP-linked OCR, maximal, and reserve 
respiratory capacity were calculated. Values are represented as mean ± SEM (n=16 replicates 
from four independent experiments). *P < 0.05 versus  SiMAT1A.  
Figure 4. MATα1 and CYP2E1 directly interact 
In vitro pull-down assay using A. immobilized recombinant MATα1 with recombinant 
CYP2E1 or B. immobilized recombinant CYP2E1 with recombinant MATα1 and IB for 
MATα1 and CYP2E1 (n=3). C. IP of total mouse liver lysate (700 μg, n=3) with anti-
CYP2E1 or anti-MATα1 Ab followed by Immunoblot (IB) analysis for MATα1 or CYP2E1. 
D. IP of isolated WT mouse liver mitochondria (300 μg, n=3) with anti-CYP2E1 or anti-
MATα1 Ab followed by IB analysis for MATα1 or CYP2E1. Normal Ig was used as a 
negative control and 10 μg of lysate was used as input control. Blots were re-probed with Ab 
used for IP.    
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Figure 5. CYP2E1 expression is negatively regulated by MATα1 and MAT1A 
knockdown-mediated mitochondrial dysfunction is dependent on CYP2E1  
A. Relative mRNA expression of 3-month old male Mat1a and Cyp2e1 in WT and Mat1a KO
liver. Results represent a total of at least three independent experiments done in duplicate. 
*
P < 0.05 versus WT. B. Protein expression of CYP2E1 in both WT and Mat1a KO mouse 
livers, 
*
P < 0.05 versus WT (n=3). C. Expression of CYP2E1 in isolated mouse liver
mitochondria in both WT and Mat1a KO. 
*
P < 0.05 versus WT (n=5). Succinate 
dehydrogenase (SDHA) and COXIV were used as mitochondrial specific markers, and 
tubulin was used as a cytosolic marker to demonstrate purity. SDHA was used as a 
housekeeping control to normalize protein expression. D. Mitochondrial CYP2E1 protein 
quantification of WT and Mat1a KO mouse liver mitochondria. Peptide to protein rollup was 
done using MSSTATS. Error bars represent standard deviation from biological replicates. 
*
P < 0.05 versus WT. E. Western blot analysis of CYP2E1 and MATα1 in WT mouse 
hepatocytes, when either Mat1a (66 hours, 50 nM) and/or Cyp2e1 (66 hours, 30 nM) were 
silenced (n=3). GAPDH was used as housekeeping control to normalize protein expression. 
*
P < 0.05 versus double scramble control (SC+SC). F. Membrane potential and 
mitochondrial ROS (mROS) levels from experiment described in E. 
*
P < 0.05 versus double
scramble control (SC+SC) (n=3).    
Figure 6. CYP2E1 is a methylated protein and level of me-CYP2E1 is reduced in Mat1a 
KO liver mitochondria  
A. IP of 5-month old male mouse liver mitochondria lysate from WT or Mat1a KO mice
(n=3) with anti-mono/di methyl arginine Ab followed by immunoblot (IB) analysis for 
CYP2E1. Amount of methylated CYP2E1 was determined first by normalizing to Ig for each 
IP and then comparing that value to total levels of CYP2E1 that had been normalized to 
SDHA.
 *
P < 0.05 versus WT. B. Intensity of the extracted precursor isotopic envelope (M,
M+1, M+2) of a representative CYP2E1 peptide in WT (left panel) and Mat1a KO (right 
panel). C. CYP2E1 protein quantification from a mitochondrial methyl-immunoprecipitation 
using WT and Mat1a KO 5-month old male mouse liver mitochondria. Peptide to protein 
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rollup was done using MSSTATS. Error bars represent standard error from biological 
replicates (n=4). D. Western blot analysis of HepG2 cells that were over-expressed with 
wither WT CYP2E1, R100N CYP2E1, R379N CYP2E1, or R100N/R379N CYP2E1 mutants 
for 48 hours in the presence or absence of MAT1A (48 hours) (n=3). GAPDH was used as a 
housekeeping control to normalize protein expression ,
*
P < 0.05 versus specific 
CYP2E1+EV control.   
Figure 7. Overexpression of MAT1A enhanced CYP2E1 degradation via the 
proteasomal pathway 
A. Western blot analysis of HepG2 cells that were co-overexpressed with CYP2E1 and
MAT1A for 48 hours before CHX addition for 5 hours in serum free media (n=3). GAPDH 
was used as housekeeping control to normalize protein expression. 
*
P < 0.05 versus 
CYP2E1+empty vector (EV) control B. Graph shows the t1/2 for CYP2E1 as compared to EV 
at time 0. All densitometric values were normalized to GADPH and expressed as % of 
CYP2E1+EV at time 0, average of 3 independent experiments are shown. Regression 
analysis using the best fit line was done to calculate the half-lives of CYP2E1 with or without 
MAT1A over-expression. *P < 0.05 versus CYP2E1+ EV. C. Western blot analysis of 
HepG2 cells that were over-expressed with or without MAT1A in addition to CYP2E1 for 42 
hours before the addition of MG132 for 6 hours (n=3). GAPDH was used as housekeeping 
control to normalize protein expression. 
*
P < 0.05 versus CYP2E1 control. D. Western blot
analysis of MATα1 using whole mouse liver showing isolated microsomal fraction. 
Endoplasmic recticulum marker (Calnexin) and cytosolic marker (Tubulin) were 
immunoblotted to demonstrate fraction purity (n=3). E. IP of isolated WT mouse liver 
microsome (300 μg, n=3) with anti-CYP2E1 Ab followed by Western blot analysis for 
MATα1 or  F. IP with anti-MATα1 Ab followed by Western blot analysis for CYP2E1. 
Normal Ig was used as a negative control and 10 μg of lystate was used as input control. 
Blots were re-probed with Ab used for IP.    
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Figure 8. MATα1 interacts with CYP2E1 in human liver and methylated CYP2E1 is 
reduced in human ALD  
A. Western blot analysis of MATα1 in whole human liver (n=3) showing both cytosolic and
mitochondrial fractions. Mitochondrial (SDHA) and cytosolic (Tubulin) specific markers 
were immunoblotted to demonstrate fraction purity. B. IP of total human liver lysate (700 μg, 
n=3) with anti-MATα1 or anti-CYP2E1 Ab followed by IB analysis for either CYP2E1 or 
MATα1. Blots were re-probed with Ab used for IP. Normal Ig was used as a negative control 
and 10 µg of lysate used as input control. C. Control (n=4) and ALD (n=5) total liver lysate 
(lys) IB for MATα1 and densitometric values were normalized to GADPH and expressed as 
% over control. D. IP with anti-mono/di methyl arginine Ab followed by IB analysis for 
CYP2E1. Amount of methylated CYP2E1 was determined first by normalizing to Ig for each 
IP and then compared to total levels of CYP2E1 that had been normalized to actin. 
*
P < 0.05
versus control. E. IP of 3.5-month old female mouse liver lysate from pair-fed or NIAAA 
mice (n=5 and 6 respectively). IP of total mouse liver lystate (700μg) with anti-mono/di 
methyl arginine Ab followed by IB analysis for CYP2E1. Amount of methylated CYP2E1 
was determined first by normalizing to Ig for each IP and then compared to total levels of 
CYP2E1 that had been normalized to GAPDH. 
*
P < 0.05 versus control.
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